Yuan Yuan Ling

Jinzhou Medical University — China

Biochemistry, Genetics and Molecular Biology · Life Sciences

14h-index4.3kcitations30works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(9), Synthesis and biological activity(5), Cancer Mechanisms and Therapy(5), Pancreatic function and diabetes(3), Telomeres, Telomerase, and Senescence(3)

Publications30 total

The Role of the TIMP1/LINC01615 Axis as a Regulator of the EMT Pathway in Gastric Cancer
Biological Procedures Online·2025· 1 citedOpen Access
Fisetin is a senotherapeutic that extends health and lifespan
EBioMedicine·2018· 915 citedOpen Access
Identification of HSP90 inhibitors as a novel class of senolytics
Nature Communications·2017· 653 citedOpen Access
The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs
Aging Cell·2015· 2.3k citedOpen Access
Synthesis and SAR of novel isoxazoles as potent c-jun N-terminal kinase (JNK) inhibitors
Bioorganic & Medicinal Chemistry Letters·2013· 21 citedOpen Access
Abstract 1810: Analysis of EGFRvIII mediated responses driven by JNK2 in Glioblastoma Multiforme.
Cancer Research·2013
Preliminary study on the identification methods for encephalomyocarditis virus
Zhonghua weishengwuxue he mianyixue zazhi·2013
Research progress in carbohydrates of virus
Int J Biologicals·2013
Synthesis and SAR of 2,4-diaminopyrimidines as potent c-jun N-terminal kinase inhibitors
MedChemComm·2011· 8 cited
Abstract 1119: Interplay between EGFRvIII and c-Met in glioblastoma multiforme
Cancer Research·2011
Small Molecule c-jun-N-Terminal Kinase Inhibitors Protect Dopaminergic Neurons in a Model of Parkinson’s Disease
ACS Chemical Neuroscience·2011· 69 citedOpen Access
Synthesis and SAR of novel quinazolines as potent and brain-penetrant c-jun N-terminal kinase (JNK) Inhibitors
Bioorganic & Medicinal Chemistry Letters·2011· 24 citedOpen Access
Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-jun N-terminal kinase inhibitors
Bioorganic & Medicinal Chemistry Letters·2010· 21 citedOpen Access
Corrections to Synthesis, Biological Evaluation, X-ray Structure, and Pharmacokinetics of Aminopyrimidine c-jun-N-terminal Kinase (JNK) Inhibitors
Journal of Medicinal Chemistry·2010
Synthesis, Biological Evaluation, X-ray Structure, and Pharmacokinetics of Aminopyrimidine c-jun-N-terminal Kinase (JNK) Inhibitors
Journal of Medicinal Chemistry·2009· 66 citedOpen Access
Research advances in the technology of antibody humanization
Int J Biologicals·2009
Synthesis and SAR of piperazine amides as novel c-jun N-terminal kinase (JNK) inhibitors
Bioorganic & Medicinal Chemistry Letters·2009· 28 citedOpen Access
Structure-Activity Relationships and X-ray Structures Describing the Selectivity of Aminopyrazole Inhibitors for c-Jun N-terminal Kinase 3 (JNK3) over p38
Journal of Biological Chemistry·2009· 70 citedOpen Access
Construction,expression and activities of three active variants of human uridine diphosphate glucuronic acid transferase 2B7
2008· 2 cited
3,5-Disubstituted quinolines as novel c-Jun N-terminal kinase inhibitors
Bioorganic & Medicinal Chemistry Letters·2007· 40 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Derek R. Duckett(12), Philip V. LoGrasso(8), Wei‐Min Chen(7), Xinyi Song(7), Michael D. Cameron(7), Claudia Ruiz(6), Lin Li(6), Theodore M. Kamenecka(6), Jeff E. Habel(5), Rong Jiang(5), Youseung Shin(5), Marcel Koenig(5), Yuanjun He(5), Ted Kamenecka(4), Douglas D. McAbee(4), Yi Zhu(3), Tamar Tchkonia(3), Sara J. McGowan(3), Heike Fuhrmann‐Stroissnigg(3), Paul D. Robbins(3)